This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of -2.68% and 0.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health
by Zacks Equity Research
Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.18, moving -1.61% from the previous trading session.
Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.
4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates
by Kaibalya Pravo Dey
Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $9.88, marking a -0.3% move from the previous day.
Why Is Viatris (VTRS) Down 16.4% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.
Viatris' (VTRS) Q4 Earnings In-Line, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 14.81% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 results are likely to be impacted by foreign exchange rate fluctuations. With the Biocon deal closed, investors await its impact on the 2023 guidance.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Viatris (VTRS) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort
by Zacks Equity Research
Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.
Zacks Earnings Trends Highlights: Disney, Take-Two, DuPont and Viatris
by Zacks Equity Research
Disney, Take-Two, DuPont and Viatris have been highlighted in this Earnings Trends article.
Making Sense of the Earnings Picture and Estimate Revisions
by Sheraz Mian
Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3 earnings for the rest of the index would be -6.0%
Making Sense of the Earnings Picture and Estimate Revisions
by Sheraz Mian
Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3 earnings for the rest of the index would be -6.0%
Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.
Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.
Viatris (VTRS) Q3 Earnings Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 4.88% and 1.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?